BRIEF-Mural Oncology Announces Enhancements To Late-Stage Clinical Trials

Reuters01-08

* MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE CLINICAL TRIALS

* STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL TRIALS DESIGNED TO GENERATE MORE MEANINGFUL CLINICAL DATA FOR LATE-STAGE

* INTENDS TO NOMINATE DEVELOPMENT CANDIDATES FOR ENGINEERED THERAPIES TARGETING INTERLEUKIN-18 AND INTERLEUKIN-12 PROGRAMS IN 2024

* REITERATES CURRENT CASH RUNWAY PROJECTION INTO 4Q 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2401959805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-08 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2401959805","market":"us","top_or_hot":-1,"title":"BRIEF-Mural Oncology Announces Enhancements To Late-Stage Clinical Trials","media":"Reuters","content":"<html><body><p>Jan 8 (Reuters) - <a href=\"https://laohu8.com/S/MURA\">Mural Oncology</a> <a href=\"https://laohu8.com/S/PLC\">PLC</a>   :</p><p>   * MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE CLINICAL TRIALS</p><p>   * STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL TRIALS DESIGNED TO GENERATE MORE MEANINGFUL CLINICAL DATA FOR  LATE-STAGE</p><p>   * INTENDS TO NOMINATE DEVELOPMENT CANDIDATES FOR  ENGINEERED THERAPIES TARGETING INTERLEUKIN-18 AND INTERLEUKIN-12 PROGRAMS IN 2024</p><p>   * REITERATES CURRENT CASH RUNWAY PROJECTION INTO 4Q 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mural Oncology Announces Enhancements To Late-Stage Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mural Oncology Announces Enhancements To Late-Stage Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-08 21:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 8 (Reuters) - Mural Oncology PLC   :   * MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE CLINICAL TRIALS   * STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL TRIALS DESIGNED TO GENERATE...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSI","symbol_name":"Stage Stores Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2401959805","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2401959805","pubTimestamp":1704721859,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 8  - Mural Oncology PLC   :   * MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE CLINICAL TRIALS   * STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL TRIALS DESIGNED TO GENERATE MORE MEANINGFUL CLINICAL DATA FOR  LATE-STAGE   * INTENDS TO NOMINATE DEVELOPMENT CANDIDATES FOR  ENGINEERED THERAPIES TARGETING INTERLEUKIN-18 AND INTERLEUKIN-12 PROGRAMS IN 2024   * REITERATES CURRENT CASH RUNWAY PROJECTION INTO 4Q 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SSI":"Stage Stores Inc","BK4139":"生物科技","MURA":"Mural Oncology"},"translate_title":"附壁肿瘤学宣布增强后期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MURA":1,"SSI":1},"content_text":"Jan 8 (Reuters) - Mural Oncology PLC   :   * MURAL ONCOLOGY ANNOUNCES ENHANCEMENTS TO LATE-STAGE CLINICAL TRIALS   * STRATEGIC CHANGES TO ARTISTRY-6 AND ARTISTRY-7 CLINICAL TRIALS DESIGNED TO GENERATE MORE MEANINGFUL CLINICAL DATA FOR  LATE-STAGE   * INTENDS TO NOMINATE DEVELOPMENT CANDIDATES FOR  ENGINEERED THERAPIES TARGETING INTERLEUKIN-18 AND INTERLEUKIN-12 PROGRAMS IN 2024   * REITERATES CURRENT CASH RUNWAY PROJECTION INTO 4Q 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2401959805"}